甲谷 太郎 (コウヤ タロウ)

北海道大学病院 内科講師

研究者基本情報

■ 学位
  • 医学博士, 北海道大学大学院医学研究院, 2022年03月
■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 00907280
J-Global ID■ 研究キーワード・分野
研究キーワード
  • 難治性不整脈に対する陽子線治療
  • パルスフィールドアブレーション
  • 心房細動
  • 心室性不整脈
  • 臨床心不全
  • SKチャネル
研究分野
  • ライフサイエンス, 循環器内科学
■ 担当教育組織

経歴

■ 経歴
経歴
  • 2025年07月 - 現在
    北海道大学病院, 循環器内科, 講師, 日本国
  • 2025年01月 - 2025年06月
    北海道大学病院, 循環器内科, 助教, 日本国
  • 2023年01月 - 2024年12月
    メイヨークリニック, 心臓血管部門, アメリカ合衆国
  • 2023年01月 - 2024年12月
    北海道大学, 循環器内科, 客員研究員
  • 2022年04月 - 2022年12月
    北海道大学, 循環器内科, 特任助教
  • 2018年04月 - 2022年03月
    北海道大学大学院医学研究院 循環病態内科学教室 大学院生
  • 2016年04月 - 2018年03月
    市立釧路総合病院 心臓血管内科
  • 2015年04月 - 2016年03月
    砂川市立病院 循環器内科
学歴
  • 2018年04月 - 2022年03月, 北海道大学大学院医学研究院 循環病態内科学教室 博士課程
  • 2007年04月 - 2013年03月, 北海道大学医学部医学科

研究活動情報

■ 受賞
  • 2023年, 日本心臓病学会, Case Report Award「優秀賞」
  • 2022年, 第35回 日本心臓財団・バイエル薬品 海外留学助成賞
  • 2022年, 公益財団法人 加藤記念バイオサイエンス振興財団 第34回 国際交流助成賞受賞
  • 2019年, 一般財団法人 北海道心臓協会, 研究開発調査助成賞受賞
■ 論文
  • Erythropoietin Resistance and Outcomes According to SGLT2 Inhibitor Use in Anemic Patients With Heart Failure.
    Toshifumi Tamura; Toshiyuki Nagai; Motoki Nakao; Shu Tahara; Yoshifumi Mizuguchi; Taro Koya; Atsushi Tada; Fusako George; Isao Yokota; Yoshiya Kato; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Ko Motoi; Yutaka Wakamatsu; Masaharu Machida; Takahiko Saito; Toshihisa Anzai
    Journal of cardiac failure, 2026年08月07日, [国際誌]
    英語, 研究論文(学術雑誌)
  • The utility of the T wave peak to T wave end interval to Q-T end interval ratio as a dynamic indicator of cardiac sympathetic activity: a preliminary study.
    Shota Saito; Taro Temma; Masaya Watanabe; Takahide Kadosaka; Motoki Nakao; Taro Koya; Kiwamu Kamiya; Toshiyuki Nagai; Toshihisa Anzai
    Heart and vessels, 2026年08月05日, [国内誌]
    英語, 研究論文(学術雑誌), Excessive cardiac sympathetic nerve activity significantly contributes to chronic heart failure (CHF) and lethal arrhythmias. However, reliable dynamic markers to assess sympathetic modulation are lacking in clinical practice. The T wave peak to T wave end interval (TpTe) to Q-T end interval ratio (TpTe/QTe) has been suggested as a surrogate marker for transmural dispersion of repolarization (TDR). We hypothesized that the TpTe/QTe reflects cardiac sympathetic nerve activity based on anatomical differences in the distribution and activation of cardiac sympathetic nerves. 12-lead Electrocardiograms (ECGs) were analyzed retrospectively in two cohorts without structural heart disease: (1) Exercise study; ECGs from patients who underwent treadmill or cardiopulmonary exercise testing between 2013 and 2023 were analyzed at baseline and 1-min post-maximal exercise. (2) β-stimulator infusion study; ECGs from patients who underwent catheter ablation (CA) of premature ventricular contractions (PVCs) or paroxysmal supraventricular tachycardias (PSVT) between 2017 and 2022 were analyzed at baseline and post-isoproterenol (ISO) infusion. In the exercise study, 45 patients (35.6% female, median age: 51) showed significant changes in the TpTe/QTe (interquartile range [IQR]: 0.20-0.30) from baseline to 1-min post-maximal exercise. In the β-Stimulator infusion study, 55 patients (63.6% female, median age: 55) had significant TpTe/QTe changes (0.19-0.33) from baseline to post-ISO infusion. The TpTe/QTe exhibited the largest change among the ECG parameters in both groups, regardless of sex, with no correlation to the left ventricular wall thickness. The TpTe/QTe may serve as a valuable dynamic indicator of cardiac sympathoexcitaion in patients without organic heart disease.
  • Different Effects of Defibrillator Shocks on the Myocardial Damage Between Subcutaneous and Transvenous Implantable Cardioverter-Defibrillators.
    Takahide Kadosaka; Masaya Watanabe; Motoki Nakao; Taro Koya; Hikaru Hagiwara; Hiroyuki Gibo; Taro Temma; Kazuya Mizukami; Hisashi Yokoshiki; Toshihisa Anzai
    Journal of cardiovascular electrophysiology, 37, 8, 1793, 1800, 2026年08月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although the implantable cardioverter defibrillators (ICD) are the only established treatment to prevent sudden cardiac death, previous studies reported that those who receive shock therapies, whether appropriate or inappropriate, have a higher risk of death. However, the difference in the influence of shock therapies between via Transvenous-ICD (TV-ICD) and Subcutaneous-ICD (S-ICD) has not been adequately examined. We aimed to investigate the influence of shocks on myocardium in patients with TV-ICD and S-ICD. METHODS: We enrolled consecutive patients who received a defibrillator or transvenous pacemaker (TV-PM) implantation between November 2020 and March 2024. A total of 74 patients were included in this study and divided into three groups: patients with TV-ICD with defibrillation testing (DFT) (TV-DFT, 27 patients), those with transvenous devices implanted without DFT (TV-no DFT, 25 patients) and those with S-ICD (22 patients). RESULTS: Delta log troponin-I (the difference of serum troponin-I levels between baseline and after implantation) was significantly increased in TV-DFT group. In patients with TV-ICD (46 patients), Delta log troponin-I was significantly correlated with total shock joules. In the multivariable linear regression analysis, a value of total shock joules was independently associated with delta troponin-I. CONCLUSION: Elevation of serum troponin-I was associated with the TV-ICD shocks and correlated with the total shock energy, but not with S-ICD shocks. Our results suggest that TV-ICD shocks are associated with greater myocardial injury compared to S-ICD shocks, and that total shock energy is an important determinant of the extent of myocardial damage.
  • Temporal Changes in Guideline-Directed Medical Therapy Score and Clinical Outcomes in Patients with Heart Failure.
    Toshifumi Tamura; Toshiyuki Nagai; Motoki Nakao; Yoshifumi Mizuguchi; Taro Koya; Atsushi Tada; Fusako George; Isao Yokota; Yoshiya Kato; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Ko Motoi; Yutaka Wakamatsu; Masaharu Machida; Takahiko Saito; Toshihisa Anzai
    European heart journal. Quality of care & clinical outcomes, 2026年06月19日, [国際誌]
    英語, 研究論文(学術雑誌), AIMS: Optimisation of guideline-directed medical therapy (GDMT) is a cornerstone of management in heart failure (HF). The GDMT scoring system was developed to quantify both the use and intensification of GDMT. This study investigated the longitudinal changes in the GDMT score and its association with clinical outcomes in contemporary practice. METHODS AND RESULTS: This multicentre prospective cohort study included 680 patients with chronic HF with reduced ejection fraction. The patients were classified into the up-titration (n = 282) and no up-titration (n = 398) groups according to changes in the GDMT score over 9 months. The GDMT score incorporated the use and dose of guideline-recommended drugs including quadruple therapy, ivabradine, and vericiguat. The primary outcome was a composite of all-cause death and hospitalisation for worsening HF. Inverse probability of treatment weighting was used to adjust for baseline differences. Up-titration rates at 9 months were 31.8% for renin-angiotensin system blockers, 28.2% for β-blockers, 10.6% for mineralocorticoid receptor antagonists, and 11.9% for sodium-glucose cotransporter 2 inhibitors. Up-titration was independently associated with baseline GDMT score, age, left ventricular ejection fraction, blood pressure, and renal function. Furthermore, up-titration was associated with a lower incidence of the primary outcome than no up-titration (adjusted HR, 0.65; 95% CI, 0.43-0.98). CONCLUSION: In this contemporary chronic HF cohort, the GDMT score incorporating guideline-recommended drugs revealed suboptimal implementation and intensification of GDMT over 9 months. Greater increases in GDMT score were associated with improved clinical outcomes, supporting the clinical relevance of longitudinal GDMT optimisation.
  • Identification of the critical isthmus in reentrant AVN-AT using PPI-TCL-guided manifest entrainment and pre-systolic potential mapping.
    Masahiro Kawasaki; Taro Temma; Ryo Sasaki; Ryudai Hirako; Taro Koya; Toshihisa Anzai
    HeartRhythm case reports, 12, 6, 667, 670, 2026年06月, [国際誌]
    英語, 研究論文(学術雑誌)
  • Prognostic Value of Mid-Range QRS Duration in Patients With Heart Failure With Reduced Ejection Fraction.
    Shota Saito; Taro Temma; Toshiyuki Nagai; Motoki Nakao; Isao Yokota; Atsushi Tada; Taro Koya; Suguru Ishizaka; Yoshifumi Mizuguchi; Fusako George; Yoshiya Kato; Yuki Takahashi; Shogo Imagawa; Ko Motoi; Yusuke Tokuda; Junichi Matsumoto; Masashige Takahashi; Hiroshi Okamoto; Masaharu Machida; Takahiko Saito; Toshihiro Shimizu; Toshihisa Anzai
    Circulation journal : official journal of the Japanese Circulation Society, 90, 6, 713, 721, 2026年04月25日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Prolonged QRS is an established marker of adverse outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the prognostic significance of modest QRS prolongation (120-149 ms; mid-range QRS) remains unclear, especially in patients without cardiac implantable electronic devices (CIEDs). This study assessed the natural prognosis associated with mid-range QRS compared with narrow QRS (<120 ms) in a recent Asian cohort of patients with HFrEF. METHODS AND RESULTS: We analyzed patients with HFrEF from the Epidemiological Multicenter Study for Tailored Treatment in Heart Failure (ELMSTAT-HF; January 2020-October 2023). QRS was measured from 12-lead electrocardiograms. Patients with wide QRS (≥150 ms) or CIEDs were excluded. The primary outcome was a composite of all-cause mortality and heart failure hospitalizations. Multivariable Cox models adjusted for the MAGGIC risk score and log-transformed N-terminal pro B-type natriuretic peptide were used. Among 415 patients, 328 had narrow QRS and 87 had mid-range QRS. Over a median follow-up of 547 days, the primary outcome occurred more frequently in the mid-range QRS group (34.5% vs. 12.5%; P<0.001). Mid-range QRS remained independently associated with adverse outcomes (hazard ratio 3.12; 95% confidence interval 1.91-5.11), consistent across non-left bundle branch block (LBBB) and LBBB subgroups. CONCLUSIONS: Mid-range QRS is an independent predictor of adverse outcomes in HFrEF, even in the absence of LBBB.
  • Early and Late Myocardial Effects of Proton Beam Cardiac Radioablation: Insights From Gene Expression Analysis.
    Tatsuhiko Hirao; Masayoshi Suda; Maryam E Rettmann; Amanda J Deisher; John A Wight; Taro Koya; Laura K Newman; Tamar Tchkonia; Jon J Kruse; Dean A Shumway; Kenneth W Merrell; Samuel J Asirvatham; James L Kirkland; Douglas L Packer; Konstantinos C Siontis
    JACC. Clinical electrophysiology, 12, 3, 552, 563, 2026年03月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Cardiac radioablation (CRA) is an emerging treatment modality for refractory ventricular tachycardia. The mechanisms underlying the antiarrhythmic effect of CRA remain incompletely understood. OBJECTIVES: The goal of this study was to investigate the nature and time course of key gene expression of apoptosis, conduction, and fibrosis after 40 Gy proton beam CRA. METHODS: In 18 swine, left ventricular (LV) targets were treated with a single-fraction 40 Gy proton beam. Myocardium was harvested from an irradiated LV target (IR-40Gy LV), the border area (IR-Border LV), and non-irradiated remote location (Remote LV) 1 to 32 weeks later. Apoptosis was assessed with the terminal deoxynucleotidyl transferase dUTP nick end labeling method that detects DNA breaks in the late phase of apoptosis. Markers of cellular survival, electrical conduction, and fibrosis were also assessed with real-time polymerase chain reaction. RESULTS: Terminal deoxynucleotidyl transferase dUTP nick end labeling staining suggested ongoing apoptosis in IR-40Gy LV through 20 to 32 weeks, with a peak at 4 to 8 weeks. Statistically significant expression reduction of TNNT2 (encoding cardiac troponin T) was noted in the IR-40Gy LV group compared with the Remote LV group at 1 to 2 weeks and through 20 to 32 weeks. IR-40Gy LV and IR-Border LV showed patterns of expression reduction of genes of myocardial conduction, including SCN5A, GJA1, and GJA5 (encoding NaV1.5, connexins 43 and 40, respectively) beginning at 4 to 8 weeks. Fibrosis genes COL1A1 and COL3A1 (encoding collagen types I and III) exhibited statistically significant expression up-regulation late after irradiation (20-32 weeks) in IR-40Gy LV relative to Remote LV. CONCLUSIONS: Apoptosis peaked at 4 to 8 weeks and continued during several months of follow-up after proton beam irradiation. There was no evidence of up-regulation of conduction markers early after irradiation. Activation of fibrosis pathways occurred several weeks after irradiation.
  • Local Calcium Chloride Infusion Enhances Acute and Chronic Efficacy of Ventricular Pulsed-Field Ablation.
    Taro Koya; Ikram U Haq; Jason A Tri; Ying Yang; Naoto Otsuka; William H Sauer; Samuel J Asirvatham; Duy T Nguyen
    Journal of cardiovascular electrophysiology, 37, 2, 374, 380, 2026年02月, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Pulsed-field ablation (PFA) offers myocardial selectivity with minimal thermal injury, but depth for ventricular lesions may be insufficient or heterogeneous at clinically tolerable field strengths. Calcium electroporation-local calcium chloride (CaCl₂) infusion after PFA-may amplify electroporation-mediated cell death while maintaining low energy settings. OBJECTIVE: To determine whether immediate post-PFA CaCl₂ infusion enhances acute and chronic ventricular lesion formation in vivo. METHODS: Nine swine underwent focal ventricular PFA (750-1000 V, biphasic, 20 μs × 50 pulses, 200 ms interpulse) via an irrigated focal catheter and benchtop electroporator. Immediately post-PFA, lesions were randomized to saline, 0.2 g Ca, or 0.4 g Ca infused locally through the catheter tip. Acute hearts were explanted for TTC analysis; surviving animals were studied at 7 days for chronic lesion geometry. RESULTS: Among 41 acute lesions (17 control, 12 Ca 0.2 g, 12 Ca 0.4 g), Ca 0.4 g increased dark-zone depth (3.5 ± 1.4 vs. 2.3 ± 0.8 mm; p = 0.038) and pale-zone depth (2.6 ± 1.3 vs. 1.3 ± 0.8 mm; p = 0.011) versus control. At 7 days (n = 33 lesions), Ca 0.4 g produced larger scars than control (width 11.6 ± 2.1 vs. 10.0 ± 1.9 mm; p = 0.027; depth 4.2 ± 1 vs. 3.0 ± 0.8 mm; p < 0.001; volume 193.6.4 ± 82.3 vs. 109.4 ± 48.2 mm³; p = 0.001). CONCLUSIONS: Local CaCl₂ infusion after ventricular PFA significantly augments acute electroporation effect and chronic lesion size at low output, supporting facilitated PFA as a strategy for deeper, more durable ventricular ablation.
  • Dose-Dependent Effects of Radiation on the Coronary Arteries: Results From a Preclinical Model of Single-Fraction Proton Beam Cardiac Radioablation.
    Tatsuhiko Hirao; Maryam E Rettmann; Amanda J Deisher; Taro Koya; Laura K Newman; Naomi M Gades; Amir Lerman; Samuel J Asirvatham; Jon J Kruse; Kenneth W Merrell; Dean A Shumway; Douglas L Packer; Konstantinos C Siontis
    Circulation. Arrhythmia and electrophysiology, 19, 1, e013995, 2026年01月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Cardiac radioablation is emerging as a treatment modality for refractory ventricular tachycardia. This study aimed to evaluate the effects of radiation on the coronary arteries in a swine model of proton beam cardiac radioablation. METHODS: Eighteen swine underwent single-fraction 30 to 40 Gy pencil-beam scanning proton therapy targeting the left ventricle and were euthanized 12 to 40 weeks later. Treatment planning was performed without restricting the dose to the coronary arteries. The maximum point dose (Dmax) to the epicardial coronary arteries was calculated. In secondary analyses, the mean (Dmean) and minimum dose received by the highest irradiated 0.01 cm3 (D0.01) of each coronary artery were also calculated. Coronary artery segments were harvested from the Dmax sites for histological analysis, and the Dmax was correlated with stenosis severity. RESULTS: Ninety-six coronary arteries were analyzed. No stenoses were observed by computed tomography imaging preirradiation. By histological analysis posteuthanasia, 25/96 (26%) coronaries sampled at their Dmax sites had ≥75% stenosis. The median Dmax was 4.7 Gy for the <75% stenosis group and 29.7 Gy for the ≥75% stenosis group (P<0.001). The AUC-ROC for the association between Dmax and stenosis ≥75% was 92.2%. A Dmax value of 20.1 Gy best predicted stenosis ≥75%, with sensitivity 92.3% and specificity 87.1%. The AUC-ROCs for the associations of Dmean and D0.01 with stenosis ≥75% were 84.8% and 91.6%, respectively. In histopathologic analysis, intimal hyperplasia was the most common coronary artery abnormality at the Dmax sites, and it was present in 61.5% of all arteries and in 93.9% of arteries with Dmax ≥20 Gy. CONCLUSIONS: In this preclinical model of proton beam cardiac radioablation, coronary stenoses occurred in a dose-dependent manner, with Dmax showing the closest correlation with stenosis ≥75%. These data provide for the first time a framework for dose constraint considerations for the coronary arteries during treatment planning for cardiac radioablation and thoracic malignancy radiation.
  • Impact of Statement-Concordant Implantable Cardioverter-Defibrillator Programming on Therapy Reduction in an Asian Cohort.
    Jiro Koya; Taro Temma; Kei Kawakami; Masahiro Kawasaki; Kintaro Shimano; Shota Saito; Daishiro Tatsuta; Kotaro Nishino; Takahide Kadosaka; Taro Koya; Motoki Nakao; Masaya Watanabe; Kiwamu Kamiya; Toshiyuki Nagai; Toshihisa Anzai
    JACC. Asia, 5, 11, 1517, 1519, 2025年09月08日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Atrial fibrillation and flutter conversion with pulsed electric field delivery: preclinical proof of concept.
    Nicholas Y Tan; Freddy Del-Carpio Munoz; Jason A Tri; Taro Koya; Naoto Otsuka; Christopher V DeSimone; Suraj Yalamuri; Elad Maor; Quim Castellvi; Antoni Ivorra; Damijan Miklavčič; Samuel J Asirvatham
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2025年08月14日, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Device-based therapies for treating atrial fibrillation (AF) episodes are limited. Using pulsed electric fields (PEF) to induce reversible electroporation of cardiac tissue may effectively terminate AF. Thus, we aimed to assess the feasibility of PEF delivery for converting atrial arrhythmias via reversible electroporation. METHODS AND RESULTS: Four swine models were used in this acute study. Custom-made decapolar catheters for PEF delivery were deployed with the following configurations: (1) Endocardial right atrium (RA) and coronary sinus (CS), n = 2; and (2) Endocardial RA and epicardial left atrium (epiLA), n = 2. AF and atrial flutter (AFL) were induced with programmed stimulation. PEF delivery was performed using the BTX 830 generator. For each attempt, a single monophasic pulse at 10 or 20 µs pulse width was administered, with voltage varied across attempts (range 750-3000 V). Successful (type 1 and 2 breaks) and unsuccessful conversion attempts were recorded. Post-PEF signal changes and arrhythmias were identified. A total of 58 AF/AFL (28 and 30 respectively) episodes were induced. Of the 37 successful conversion attempts, 33 (89.1%) were type 1 breaks. Conversion success probabilities generally increased with higher voltages for both configurations. Greater than 70% conversion success was seen with ≥ 1500 V for the RA/CS configuration and ≥ 2000 V for the RA/epiLA configuration. Arrhythmias including intra-atrial delay and high-grade atrioventricular block were seen, usually following successive PEF deliveries. Significant muscle stimulation was provoked with the current experimental setup. CONCLUSION: Termination of atrial arrhythmias with PEF delivery is feasible, although further work is required to optimize its efficacy and safety.
  • Neuropeptide Y Drives Ventricular Arrhythmogenesis in Chronic Ischemic Heart Failure via Calcium Mishandling.
    Jiro Koya; Taro Temma; Kei Kawakami; Fuyuki Karube; Zen-Ichi Tanei; Masahiro Kawasaki; Kintaro Shimano; Shota Saito; Daishiro Tatsuta; Kotaro Nishino; Hiroyuki Natsui; Takahide Kadosaka; Taro Koya; Motoki Nakao; Masaya Watanabe; Kiwamu Kamiya; Toshiyuki Nagai; Shinya Tanaka; Fumino Fujiyama; Toshihisa Anzai
    Heart rhythm, 22, 12, e1179-e1192, 2025年08月11日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Ventricular arrhythmias (VAs) in chronic ischemic heart failure (HF) are associated with high mortality and often refractory to β-blocker treatment, highliting the need for alternative therapeutic targets. OBJECTIVE: This study investigates the role of neuropeptide Y (NPY), a neurotransmitter released during sympathoexcitation, in the pathogenesis of VAs associated with ischemic chronic HF following myocardial infarction (MI). METHODS: Using a mouse model of ischemic chronic HF after coronary ligation, we employed biochemical, electrophysiological, and calcium (Ca2+) imaging analyses to investigate the proarrhythmic mechanisms of NPY. RESULTS: Immunohistochemical staining revealed a significantly elevated NPY expression in both the MI and border zone, consistent with findings in human autopsy samples. In cardiomyocytes isolated from ischemic HF mice, NPY treatment increased Ca2+ waves at a dose that did not elicit this response in normal heart cardiomyocytes, an effect suppressed by NPY Y1 receptor blocker. Additionally, the NPY treatment elevated the frequency of delayed afterdepolarizations at the membrane potential level. Similarly, NPY induced VAs that were suppressed by the NPY Y1 receptor blocker in Langendorff-perfused chronic ischemic failed hearts at a concentration that had no effect in normal hearts. CONCLUSION: We identified structural and functional changes in NPY within an chronic ischemic HF model, leading to increased arrhythmogenicity through Ca2+ mishandling. Therefore, targeting NPY signaling may offer a novel therapeutic approach for treating VAs in patients with chronic ischemic HF.
  • Clinical Phenotyping and Treatment Response in Patients With Chronic Heart Failure.
    Daishiro Tatsuta; Motoki Nakao; Toshiyuki Nagai; Yoshifumi Mizuguchi; Isao Yokota; Taro Koya; Atsushi Tada; Suguru Ishizaka; Fusako George; Yoshiya Kato; Shogo Imagawa; Ko Motoi; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Masaharu Machida; Hiroshi Okamoto; Takahiko Saito; Toshihisa Anzai
    JACC. Advances, 4, 8, 101972, 101972, 2025年08月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: There are little data on clinically meaningful heart failure (HF) phenogroups, which are associated with treatment response across the wide spectrum of left ventricular (LV) ejection fraction. OBJECTIVES: The authors aimed to identify the phenotypes of patients with HF with different prognoses and responses to medical therapies. METHODS: We examined consecutive 2,301 chronic HF patients from the ELMSTAT-HF (EpidemioLogical Multicenter Study for Tailored Treatment in Heart Failure) registry, a prospective multicenter cohort in which 2,317 patients were enrolled between January 2020 and September 2024. Latent class analysis was performed using 99 clinical features. The primary outcome was a composite of all-cause death and hospitalization for worsening HF. RESULTS: The analysis subclassified the patients into 8 phenogroups: group 1, characterized by younger age with obesity; 2, less structural abnormality and comorbidity; 3, younger age with LV dilation; 4, LV hypertrophy; 5, older age with small LV and diastolic dysfunction; 6, ischemic cardiomyopathy; 7, advanced LV remodeling and ventricular arrhythmias; and 8, atrial myopathy. During a median follow-up of 597 (IQR: 302-932) days, the incidence of the primary outcome significantly differed between the phenogroups (P < 0.001). In phenogroup 5, patients taking beta-blockers or sodium-glucose cotransporter 2 inhibitors had a significantly higher rate of hospitalization for worsening HF (HR: 2.20; 95% CI: 1.04-4.68; HR: 4.27; 95% CI: 2.02-9.05, respectively). CONCLUSIONS: We identified 8 phenogroups with distinct clinical outcomes in patients with HF. This phenotyping provides appropriate risk stratification and may aid clinical decision-making in patients with HF.
  • Battery Longevity in Modern Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy-Defibrillators.
    Kotaro Nishino; Taro Temma; Masaya Watanabe; Motoki Nakao; Masahiro Kawasaki; Kintaro Shimano; Kei Kawakami; Shota Saito; Jiro Koya; Daishiro Tatsuta; Hiroyuki Natsui; Takuya Koizumi; Takahide Kadosaka; Taro Koya; Kiwamu Kamiya; Toshiyuki Nagai; Toshihisa Anzai
    Journal of arrhythmia, 41, 4, e70175, 2025年08月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Battery longevity in high-voltage devices (HVDs), specifically implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds), is critical for reducing the frequency of generator replacements, minimizing procedural risks, and enhancing patient outcomes. Despite technological advancements, significant variability in battery performance remains among the major manufacturers. This study aimed to evaluate the battery longevity among ICDs and CRT-Ds from the major manufacturers implanted at a single institution and identify the factors influencing battery depletion. METHODS: We conducted a retrospective analysis of 353 patients implanted with HVDs (63 Abbott, 150 Boston Scientific, 140 Medtronic) at Hokkaido University Hospital between 2012 and 2021. Kaplan-Meier curves and Cox proportional hazards models were used to analyze the device longevity, with a primary endpoint of the time to battery depletion, defined by the elective replacement indicator. A multivariate analysis adjusted for the potential confounders. RESULTS: Boston Scientific devices exhibited a significantly longer battery life than Abbott and Medtronic devices (p < 0.001), with a 6-year replacement-free survival of 99% for ICDs and 93% for CRT-Ds. A multivariate analysis identified the device manufacturer, device type (ICD vs. CRT-D), and ventricular pacing rate as independent predictors of battery depletion (p < 0.001). CONCLUSION: Battery longevity differed significantly by the manufacturer, which may influence device selection. Devices with a longer battery life may help reduce the replacement frequency and could potentially contribute to improved patient outcomes and cost-effectiveness.
  • Serum Vasoactive Intestinal Peptide as a Novel Biomarker for Low-Voltage Areas in Patients With Atrial Fibrillation.
    Kotaro Nishino; Taro Temma; Hiroyuki Natsui; Masaya Watanabe; Motoki Nakao; Masahiro Kawasaki; Kintaro Shimano; Kei Kawakami; Shota Saito; Jiro Koya; Daishiro Tatsuta; Takuya Koizumi; Takahide Kadosaka; Taro Koya; Satonori Tsuneta; Kiwamu Kamiya; Toshiyuki Nagai; Toshihisa Anzai
    Journal of the American Heart Association, 14, 7, e039192, 2025年04月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Low-voltage areas in the left atrium predict atrial fibrillation recurrence after catheter ablation and are associated with adverse outcomes like death, heart failure, and stroke. Detecting low-voltage areas (LVAs) typically requires invasive procedures, highlighting the need for a simple, minimally invasive marker. Vasoactive intestinal peptide (VIP), a neuropeptide released during parasympathetic stimulation, affects electrophysiological remodeling in atrial fibrillation. We hypothesized that serum VIP could serve as a biomarker for detecting LVAs in these patients. METHODS AND RESULTS: This prospective, cross-sectional study was conducted at Hokkaido University Hospital between August 2021 and September 2023. We included 108 patients with atrial fibrillation scheduled for catheter ablation. Blood samples were collected during ablation to measure VIP using an ELISA. Electroanatomical mapping identified LVAs, defined as regions with bipolar voltage ≤0.5 mV and occupying >5% of the left atrial surface. Statistical analyses evaluated the relationship between VIP and LVAs. Fifty-one patients (47%) had LVAs, with significantly higher serum VIP levels than those without (335.1 versus 247.7 pg/mL, P<0.001). VIP levels and female sex were statistically significant factors of LVAs. Adding VIP to the existing score significantly improved its discrimination (area under the curve: 0.784 versus 0.707, P<0.001). CONCLUSIONS: Serum VIP levels are higher in patients with atrial fibrillation with LVAs, suggesting its potential as a noninvasive biomarker for detecting these areas and improving clinical management.
  • Effects of In Vivo Contact Force on Pulsed-Field Ablation Efficacy in Porcine Ventricles.
    Taro Koya; Naoto Otsuka; Jason A Tri; Yang Ying; Elyana Espinoza; Samuel J Asirvatham; Duy T Nguyen
    Journal of cardiovascular electrophysiology, 36, 3, 642, 649, 2025年03月, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Pulsed-field ablation (PFA) is an innovative non-thermal method for arrhythmia treatment. The efficacy of various PFA configurations in relation to contact force (CF) has not been well-studied in vivo. OBJECTIVES: This study evaluated the effect of CF on acute bipolar PFA lesions in both a vegetal and an in vivo porcine heart model. METHODS: Bipolar PFA (500 V, 20 μs for 50 pulses) was applied to eight porcine ventricles, with CF categorized as standard (5-15 g), high (16-30 g), or very high (> 30 g) using the CARTO 3 system. PFA lesions were assessed by gross pathology, histology, and post-ablation voltage amplitude. Additionally, a vegetal model using oscillating russet potatoes replicated the motion of a beating heart to compare lesion parameters under dynamic conditions and various PFA configurations (monopolar vs. bipolar). RESULTS: A total of 61 in vivo bipolar PFA lesions across all groups were analyzed. No significant differences in lesion surface diameter, depth, or volume were found among CF groups. In the vegetal model, monopolar setting had a better correlation between CF and lesion depth compared to bipolar setting. In addition, oscillations and catheter position (perpendicular or parallel) significantly affected lesion dimensions. CONCLUSION: Increasing CF has a minimal effect on the size of acute bipolar PFA lesions in the porcine ventricle, suggesting that, for bipolar PFA, adequate CF is more critical than its intensity in a beating heart. For monopolar PFA, greater CF can impact lesion depth.
  • Prognostic Value of Reticulocyte Production Ability in Patients with Chronic Heart Failure.
    Motoki Nakao; Toshiyuki Nagai; Atsushi Tada; Taro Koya; Suguru Ishizaka; Yoshifumi Mizuguchi; Fusako George; Yoshiya Kato; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Ko Motoi; Hiroshi Okamoto; Masaharu Machida; Takahiko Saito; Toshihisa Anzai
    The Canadian journal of cardiology, 41, 7, 1274, 1284, 2025年02月07日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Anemia is frequently observed and associated with mortality in patients with heart failure (HF). Although the quality of erythropoiesis is an intrinsic aspect of anemia's pathophysiology, its prognostic value in HF patients is unclear. METHODS: Between January 2020 and October 2023, 1,328 symptomatic patients with chronic HF from a multicenter registry were prospectively examined. The reticulocyte production ability was evaluated by calculating the reticulocyte production index (RPI) using reticulocyte counts and serum hematocrit level. Patients were divided into four groups based on the presence or absence of anemia and the median RPI. The primary outcome was a composite of all-cause death and hospitalization for worsening HF. RESULTS: During a median follow-up of 551 (interquartile range 321-712) days, the primary outcome occurred in 219 patients. The incidence of the primary outcome was high among patients in the anemia and higher RPI group (≥ 0.978) (P <0.001). Higher RPI was independently associated with a higher risk of the primary outcome, even after adjusting for prognostic covariates (adjusted HR 1.37; 95% CI 1.05-1.78). Erythrocyte counts were significantly higher in patients with higher RPI in the groups without anemia (P <0.001); however, no significant differences were observed between the groups with anemia (P = 0.923). Serum iron levels and transferrin saturation did not significantly differ between the RPI groups with or without anemia. CONCLUSIONS: Higher RPI, which may reflect impaired maturation or a shortened lifespan of erythrocytes, was associated with worse clinical outcomes in HF patients irrespective of iron status.
  • Characteristics of In Vivo Lesion Formation With a Temperature-Controlled Diamond-Tip Radiofrequency Ablation Catheter in the Ventricle: A Preclinical Model.
    Tatsuhiko Hirao; Maryam E Rettmann; Megan M Schmidt; Omar Z Yasin; Gurukripa N Kowlgi; Naoto Otsuka; Taro Koya; Laura K Newman; Douglas L Packer; Konstantinos C Siontis
    Circulation. Arrhythmia and electrophysiology, 18, 2, e013120, 2025年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Power-controlled radiofrequency ablation with irrigated-tip catheters has been the norm for ventricular ablation for almost 2 decades. New catheter technology has recently integrated more accurate tissue temperature sensing enabling temperature-controlled irrigated ablation. We aimed to investigate the in vivo ablation parameters and lesion formation characteristics in ventricular myocardium using a novel temperature-controlled radiofrequency catheter. METHODS: Twenty canines were divided into 3 groups: 4 noninfarcted, acute (phase I); 8 noninfarcted, chronic (phase II); and 8 infarcted, chronic (phase III). Lesions were delivered with a temperature-controlled radiofrequency system utilizing a chemical vapor deposit diamond for efficient thermal diffusivity. In phase I, 17 ablation settings were tested (temperature set points, 50/60/70 °C; ablation duration, 15/30/60/90/120 s; and power limit, 30/50 W). Four and one of these sets of parameters were further tested in phases II and III, respectively. Lesions were assessed by ex vivo contrast-enhanced magnetic resonance imaging and gross pathology 5 weeks after ablation in phases II/III. RESULTS: Across all phases, 111 ablation lesions were delivered. Ablation with the power limit of 50 W, the temperature set point of 60 °C, and the duration of 60 s produced significantly larger and deeper lesions (mean, 569.2 mm3; mean maximal depth, 9.8 mm) compared with 50 W/60 °C/30 s (mean, 340.4 mm3; mean maximal depth, 8.3 mm) and 50 W/50 °C/60 s (mean, 227 mm3; mean maximal depth, 6.9 mm), with P<0.05 for all pairwise comparisons. Ablation of infarcted myocardium in phase III (50 W/60 °C/30 s) resulted in smaller impedance and bipolar electrogram amplitude changes and lesion size compared with ablation in normal myocardium with the same settings. No steam pop, myocardial perforation, or char formation was observed in any of the 111 ablations across all phases. CONCLUSIONS: In vivo radiofrequency ablation in a canine model with a diamond-tip temperature-controlled catheter using a temperature set point of 60 °C and a power limit of 50 W created large lesions without steam pop risk in both normal and infarcted ventricular myocardia.
  • Local calcium chloride infusion after pulsed field ablation enhances acute efficacy of cardiac electroporation.
    Taro Koya; Naoto Otsuka; Jason A Tri; William H Sauer; Samuel J Asirvatham; Duy T Nguyen
    Journal of cardiovascular electrophysiology, 35, 12, 2354, 2360, 2024年10月03日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Pulsed field ablation (PFA) has emerged as an innovative therapy for cardiac arrhythmias. Drawing parallels with PFA's application in solid tumors, calcium chloride (CaCl2) as an adjuvant therapy, known as calcium electroporation, may amplify PFA's apoptotic effects. We propose that PFA in the atrium could enhance calcium uptake through PFA-created pores, thereby increasing ablation efficacy even at reduced power levels by exploiting PFA's permeabilization effects. METHODS: We conducted in vivo ablations on the atria of seven pigs using low PFA power (250 V, 20 μs for 50 pulses at 200 ms intervals). Post-PFA, we randomly administered an infusion of either 200 mg/2 ml CaCl2 (calcium group) or saline (control) directly to the ablation site via the catheter tip. We evaluated reduction in electrogram voltage amplitude, electrocardiography (ECG) parameters, ablation lesion parameters, and histology after PFA. RESULTS: Nineteen lesions from control and calcium groups were examined. Control lesions showed no voltage decrease post-PFA, whereas calcium-treated lesions exhibited a significant voltage reduction. Gross pathology indicated marked differences in maximum lesion surface diameter, depth, and volume between the lesion groups. Histologically, calcium group lesions were characterized by a more severe acute PFA response with contraction band necrosis, myocytolysis and nuclear pyknosis in adjacent myocardium, in addition to microhemorrhages. CONCLUSION: Infusing calcium chloride locally after PFA markedly improves the immediate efficacy of electroporation in porcine atria. This study suggests that calcium electroporation could bolster PFA outcomes without higher energy levels, potentially diminishing associated risks. These preliminary findings warrant further research into the long-term efficacy and potential clinical application of calcium electroporation in PFA.
  • Normalization of increasing shocking coil impedance with full output synchronized shock.
    Takahide Kadosaka; Masaya Watanabe; Motoki Nakao; Taro Koya; Taro Temma; Toshihisa Anzai
    Journal of cardiovascular electrophysiology, 35, 11, 2251, 2253, 2024年08月21日, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Impedance is a crucial parameter in cardiovascular implantable electronic devices (CIEDs). Clinically, most CIEDs measure impedance using low voltage sub-threshold measurement (LVSM). Although the LVSM of shock impedance (LVSM-SI) is generally comparable with high voltage shock impedance (HVSI), LVSM-SI might be inaccurate if peri-lead tissue degeneration occurs. METHODS AND RESULTS: We present a case of elevated LVSM-SI occurring 8 years post-lead implantation, possibly attributed to encapsulation of the right ventricular lead coil. After 0.1 J shock was delivered, a full output synchronized shock was administered to measure HVSI, revealing a normal value. Furthermore, LVSM-SI was normalized and maintained within the normal range during long-term follow-up. CONCLUSION: Our findings suggest conducting a full-output synchronized shock test to assess HVSI when abnormal LVSM-SI is detected in the remote phase post-ICD implantation, which may be considered to help normalize LVSM shock impedance.
  • Differential impacts of self-care behavior on clinical outcomes in patients with and without recent heart failure hospitalization.
    Taro Koya; Toshiyuki Nagai; Atsushi Tada; Motoki Nakao; Suguru Ishizaka; Yoshifumi Mizuguchi; Hiroyuki Aoyagi; Fusako George; Shogo Imagawa; Yusuke Tokuda; Yoshiya Kato; Masashige Takahashi; Hiroto Sakai; Masaharu Machida; Kenichi Matsutani; Takahiko Saito; Hiroshi Okamoto; Toshihisa Anzai
    International journal of cardiology, 415, 132452, 132452, 2024年08月14日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although clinical guidelines recommend self-care assessment for patients with chronic heart failure (CHF), its prognostic significance remains controversial. This study aimed to compare the prognostic significance of self-care behavior on mortality between patients with and without a history of recent hospitalization for heart failure (HF). METHODS: We analyzed consecutive 1907 CHF patients from a Japanese multicenter registry (January 2020-June 2023) using the 9-item European Heart Failure Self-care Behavior Scale (EHFScBS-9) at enrolment. Suboptimal self-care behavior was defined as a score < 70 on the EHFScBS-9. Patients were divided into recent (within 30 days post-discharge, n = 664) and no recent hospitalization for HF groups (n = 1263), respectively. The primary outcome was a composite of all-cause death and rehospitalization for HF. RESULTS: During a median follow-up period of 427 (interquartile range 273-630) days, the primary outcome occurred in 100 patients. Patients with suboptimal self-care behavior exhibited a higher incidence of the primary outcome in the recent hospitalization for HF group (p = 0.020) but not in the no recent hospitalization for HF group (P = 0.16). Multivariable regressions showed suboptimal self-care behavior was independently associated with the primary outcome in the recent hospitalization for HF group with a significant interaction (P = 0.029). CONCLUSION: In patients recently hospitalized for HF, but not in those without a recent hospitalization history for HF, suboptimal self-care behavior was associated with adverse events. This indicates the importance of self-care education for these patients.
  • Influence of epicardial adipose tissue inflammation and adipocyte size on postoperative atrial fibrillation in patients after cardiovascular surgery
    Hiroyuki Natsui; Masaya Watanabe; Takashi Yokota; Satonori Tsuneta; Yoshizuki Fumoto; Haruka Handa; Matsushima Shouji; Jiro Koya; Kotaro Nishino; Daishiro Tatsuta; Takuya Koizumi; Takahide Kadosaka; Motoki Nakao; Taro Koya; Taro Temma; Yoichi M. Ito; Hatanaka C. Kanako; Yutaka Hatanaka; Shingu Yasushige; Satoru Wakasa; Shuhei Miura; Takahiko Masuda; Naritomo Nishioka; Shuichi Naraoka; Kayoko Ochi; Tomoko Kudo; Tsugumine Ishikawa; Toshihisa Anzai
    Physiological Reports, 12, 6, e15957, Wiley, 2024年03月28日, [国際誌]
    英語, 研究論文(学術雑誌), Abstract

    Epicardial adipose tissue (EAT) is an active endocrine organ that is closely associated with occurrence of atrial fibrillation (AF). However, the role of EAT in the development of postoperative AF (POAF) remains unclear. We aimed to investigate the association between EAT profile and POAF occurrence in patients who underwent cardiovascular surgery. We obtained EAT samples from 53 patients to evaluate gene expression, histological changes, mitochondrial oxidative phosphorylation (OXPHOS) capacity in the EAT, and protein secretion in EAT‐conditioned medium. EAT volume was measured using computed tomography scan. Eighteen patients (34%) experienced POAF within 7 days after surgery. Although no significant difference was observed in EAT profile between patients with and without POAF, logistic regression analysis identified that the mRNA expression levels of tumor necrosis factor‐alpha (TNF‐α) were positively correlated and adipocyte size in the EAT was inversely correlated with onset of POAF, respectively. Mitochondrial OXPHOS capacity in the EAT was not associated with POAF occurrence; however, it showed an inverse correlation with adipocyte size and a positive correlation with adiponectin secretion. In conclusion, changes in the secretory profile and adipocyte morphology of the EAT, which represent qualitative aspects of the adipose tissue, were present before the onset of AF.
  • 日本人高齢患者における植え込み型除細動器の有用性(Benefit of Implantable Cardioverter-defibrillator in Elderly Japanese Patients)
    甲谷 次郎; 天満 太郎; 立田 大志郎; 西野 広太郎; 夏井 宏征; 門坂 崇秀; 小泉 拓也; 甲谷 太郎; 中尾 元基; 渡邉 昌也; 安斉 俊久
    日本循環器学会学術集会抄録集, 87回, PJ113, 4, (一社)日本循環器学会, 2023年03月
    英語
  • Optogenetic termination of atrial tachyarrhythmias by brief pulsed light stimulation
    Motoki Nakao; Masaya Watanabe; Lucile Miquerol; Hiroyuki Natsui; Takuya Koizumi; Takahide Kadosaka; Taro Koya; Hikaru Hagiwara; Rui Kamada; Taro Temma; Antoine A.F. de Vries; Toshihisa Anzai
    Journal of Molecular and Cellular Cardiology, Elsevier BV, 2023年03月
    研究論文(学術雑誌)
  • Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats
    Takuya Koizumi; Masaya Watanabe; Takashi Yokota; Masumi Tsuda; Haruka Handa; Jiro Koya; Kotaro Nishino; Daishiro Tatsuta; Hiroyuki Natsui; Takahide Kadosaka; Taro Koya; Motoki Nakao; Hikaru Hagiwara; Rui Kamada; Taro Temma; Shinya Tanaka; Toshihisa Anzai
    Frontiers in Cardiovascular Medicine, 10, Frontiers Media SA, 2023年02月06日
    研究論文(学術雑誌), Introduction

    Recent studies have demonstrated that sodium-glucose co-transporter-2 inhibitors (SGLT2-i) reduce the risk of atrial fibrillation (AF) in patients with diabetes mellitus (DM), in which oxidative stress due to increased reactive oxygen species (ROS) contributes to the pathogenesis of AF. We aimed to further investigate this, and examine whether the SGLT2-i empagliflozin suppresses mitochondrial-ROS generation and mitigates fibrosis.

    Methods

    A high-fat diet and low-dose streptozotocin treatment were used to induce type-2 DM (T2DM) in Sprague-Dawley rats. The rats were randomly divided into three groups: control, DM, and DM treated with empagliflozin (30 mg/kg/day) for 8 weeks. The mitochondrial respiratory capacity and ROS generation in the atrial myocardium were measured using a high-resolution respirometer. Oxidative stress markers and protein expression related to mitochondrial biogenesis and dynamics as well as the mitochondrial morphology were examined in the atrial tissue. Additionally, mitochondrial function was examined in H9c2 cardiomyoblasts. Atrial tachyarrhythmia (ATA) inducibility, interatrial conduction time (IACT), and fibrosis were also measured.

    Results

    Inducibility of ATA, fibrosis, and IACT were increased in rats with DM when compared to controls, all of which were restored by empagliflozin treatment. In addition, the rats with DM had increased mitochondrial-ROS with an impaired complex I-linked oxidative phosphorylation capacity. Importantly, empagliflozin seemed to ameliorate these impairments in mitochondrial function. Furthermore, empagliflozin reversed the decrease in phosphorylated AMPK expression and altered protein levels related to mitochondrial biogenesis and dynamics, and increased mitochondrial content. Empagliflozin also improved mitochondrial function in H9c2 cells cultured with high glucose medium.

    Discussion

    These data suggest that empagliflozin has a cardioprotective effect, at least in part, by reducing mitochondrial ROS generation through AMPK signaling pathways in the atrium of diabetic rats. This suggests that empagliflozin might suppress the development of AF in T2DM.
  • Fragmented QRS on 12-lead electrocardiogram predicts long-term prognosis in patients with cardiac sarcoidosis.
    Hikaru Hagiwara; Masaya Watanabe; Takahide Kadosaka; Takuya Koizumi; Yuta Kobayashi; Taro Koya; Motoki Nakao; Satonori Tsuneta; Yoshiya Kato; Hirokazu Komoriyama; Rui Kamada; Toshiyuki Nagai; Kohsuke Kudo; Toshihisa Anzai
    Heart and vessels, 2023年01月13日, [国内誌]
    英語, 研究論文(学術雑誌), Fragmented QRS (fQRS) on a 12-lead electrocardiogram is a known marker of fatal arrhythmias or cardiac adverse events in ischemic and non-ischemic cardiomyopathy patients. Nonetheless, the association between fQRS and clinical outcomes in patients with cardiac sarcoidosis (CS) remains unclear. Herein, we investigated whether fQRS is associated with long-term clinical outcomes in CS patients. A total of 78 patients who received immunosuppressive therapy (IST) for clinically diagnosed CS were retrospectively examined. Patients were classified into two groups according to the presence (n = 19) or absence (n = 59) of fQRS on electrocardiogram before IST. The primary outcome was the composite event of all-cause death, ventricular tachyarrhythmias (VTs), and hospitalization for heart failure. Results of late gadolinium enhancement on cardiac magnetic resonance imaging were also analyzed. During a median follow-up period of 3.7 years (interquartile range: 1.6-6.2 years), the primary outcome occurred more frequently in patients with fQRS than in those without (47% vs. 13%, log-rank p = 0.002). Multivariable Cox regression analyses showed that fQRS was an independent determinant of the primary outcome. The incidence of VTs, within 12 months of IST initiation, was comparable between the two groups; however, late-onset VTs, defined as those occurring ≥ 12 months after IST initiation, occurred more frequently in the fQRS group (21% vs. 2%, log-rank p = 0.002). The scar zone and scar border zone were greater in patients with fQRS than in those without it. In conclusion, our analysis suggests that fQRS is an independent predictor of adverse events, particularly late-onset VTs, in patients with CS.
  • Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes.
    Takahide Kadosaka; Masaya Watanabe; Hiroyuki Natsui; Takuya Koizumi; Motoki Nakao; Taro Koya; Hikaru Hagiwara; Rui Kamada; Taro Temma; Fuyuki Karube; Fumino Fujiyama; Toshihisa Anzai
    American journal of physiology. Heart and circulatory physiology, 324, 3, H341-H354, 2023年01月06日, [国際誌]
    英語, 研究論文(学術雑誌), Diabetic cardiomyopathy has been reported to increase the risk of fatal ventricular arrhythmia. The beneficial effects of the selective sodium-glucose co-transporter 2 inhibitor have not been fully examined in the context of anti-arrhythmic therapy, especially its direct cardioprotective effects despite the negligible SGLT2 expression in cardiomyocytes. We aimed to examine the anti-arrhythmic effects of empagliflozin (EMPA) treatment on diabetic cardiomyocytes, with a special focus on Ca2+ handling. We conducted echocardiography and hemodynamic studies and studied electrophysiology, Ca2+ handling, and protein expression in C57BLKS/J-leprdb/db mice (db/db mice) and their non-diabetic lean heterozygous Leprdb/+ littermates (db/+ mice). Preserved systolic function with diastolic dysfunction was observed in 16-week-old db/db mice. During arrhythmia induction, db/db mice had significantly increased premature ventricular complexes (PVCs) than controls, which was attenuated by EMPA. In protein expression analyses, calmodulin-dependent protein kinase II (CaMKII) Thr287 autophosphorylation and CaMKII-dependent RyR2 phosphorylation (S2814) were significantly increased in diabetic hearts, which were inhibited by EMPA. Additionally, global O-GlcNAcylation significantly decreased with EMPA treatment. Furthermore, EMPA significantly inhibited ventricular cardiomyocyte glucose uptake. Diabetic cardiomyocytes exhibited increased spontaneous Ca2+ events and decreased sarcoplasmic reticulum (SR) Ca2+ content, along with impaired Ca2+ transient, all of which normalized with EMPA treatment. Notably, most EMPA-induced improvements in Ca2+ handling were abolished by the addition of an O-GlcNAcase (OGA) inhibitor. In conclusion, EMPA attenuated ventricular arrhythmia inducibility by normalizing the intracellular Ca2+ handling, and we speculated that this effect was, at least partly, due to the inhibition of O-GlcNAcylation via the suppression of glucose uptake into cardiomyocytes.
  • Closed VSDを合併した右室二腔症の手術症例
    齋藤 翔太; 石坂 傑; 下野 裕依; 甲谷 太郎; 神谷 究; 阿部 慎司; 加藤 伸康; 永井 利幸; 若狭 哲; 安斉 俊久
    日本成人先天性心疾患学会雑誌, 12, 1, 200, 200, (一社)日本成人先天性心疾患学会, 2023年01月
    日本語
  • Applicability of new proposed criteria for iron deficiency in Japanese patients with heart failure.
    Atsushi Tada; Toshiyuki Nagai; Taro Koya; Motoki Nakao; Suguru Ishizaka; Yoshifumi Mizuguchi; Hiroyuki Aoyagi; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Yoshiya Kato; Masaharu Machida; Kenichi Matsutani; Takahiko Saito; Toshihisa Anzai
    ESC heart failure, 2022年12月10日, [国際誌]
    英語, 研究論文(学術雑誌), AIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF). A recent study showed that ID defined by the current guideline criteria was not associated with worse clinical outcomes, and new ID criteria was proposed in patients with HF. However, the external applicability of the new proposed criteria is unclear. We sought to investigate the applicability of the proposed ID criteria in Japanese patients with HF. METHODS AND RESULTS: We prospectively examined 763 patients with chronic HF from a Japanese multicentre registry. The proposed ID criteria were transferrin saturation (TSAT) < 20% and serum iron ≤13 mmol/L and the guideline ID criteria were serum ferritin <100 ng/mL or, when ferritin was 100-299 ng/mL, TSAT <20%. Among all patients (456 male, mean age 71 ± 13 years), 213 (28%) and 444 (58%) met the proposed and guideline ID criteria, respectively. During a median follow-up period of 436 days (interquartile range 297-565), the primary outcome of all-cause mortality occurred in 56 (7%) patients. There was no significant difference in the primary outcome between the patients with and without guideline ID criteria (P = 0.32), whereas patients with serum iron ≤10 μmol/L showed higher mortality (P = 0.002). In multivariable Cox regressions, the proposed ID criteria, but not guideline ID criteria, were independently associated with the risk of all-cause mortality (HR 2.01, 95% CI 1.16-3.51 and HR 1.32, 95% CI 0.76-2.28, respectively), even after adjustment for covariates. CONCLUSIONS: When defined by the proposed criteria and not the guideline criteria, ID was associated with higher mortality in patients with chronic HF, suggesting that the proposed ID criteria is applicable to the Japanese population.
  • Predictors of cardiovascular mortality after an electrical storm in patients with structural heart disease.
    Takuya Koizumi; Rui Kamada; Masaya Watanabe; Hisashi Yokoshiki; Taro Temma; Hikaru Hagiwara; Taro Koya; Motoki Nakao; Takahide Kadosaka; Hiroyuki Natsui; Masayuki Takahashi; Kazuya Mizukami; Hirofumi Mitsuyama; Toshihisa Anzai
    Journal of cardiology, 80, 2, 167, 171, 2022年08月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Electrical storms (ESs) in patients with structural heart disease (SHD) have been reported to be associated with a poor prognosis. However, the detailed cause of death and influence of implantable cardioverter defibrillator (ICD) therapy in ES patients have not been fully investigated. Therefore, we sought to explore the detailed clinical course after an ES and the impact of the ICD therapy in patients with SHDs. METHODS: We retrospectively analyzed 31 consecutive patients with ESs who had undergone an ICD implantation. ESs were defined as three or more ventricular arrhythmias within 24 h. RESULTS: During a mean follow up of 4.5 years, 13 patients died. Among them, cardiovascular death (CVD) was observed in 11/13 (85%), and the leading cause of the CVD was end-stage heart failure. A New York Heart Association class ≥III at the time of the ES occurrence (HR 6.51 95% CI 1.94-25.1, p = 0.003) and any shock therapy (HR 5.94 95% CI 1.06-112.2, p = 0.04) were associated with CVD. CONCLUSION: In the current single center study, the major cause of death in ES patients with SHDs was end-stage heart failure. Any shock therapy was associated with CVD. Arrhythmia management to avoid ICD shocks might reduce the mortality in ES patients.
  • Stimulation of the mitochondrial calcium uniporter mitigates chronic heart failure-associated ventricular arrhythmia in mice.
    Hikaru Hagiwara; Masaya Watanabe; Yoichiro Fujioka; Takahide Kadosaka; Takuya Koizumi; Taro Koya; Motoki Nakao; Rui Kamada; Taro Temma; Kazufumi Okada; Jose Antonio Moreno; Ohyun Kwon; Hisakata Sabe; Yusuke Ohba; Toshihisa Anzai
    Heart rhythm, 19, 10, 1725, 1735, 2022年05月31日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: An aberrant increase in the diastolic calcium concentration ([Ca2+]i) level is a hallmark of heart failure (HF) and the cause of delayed afterdepolarization and ventricular arrhythmia (VA). Although mitochondria play a role in regulating [Ca2+]i, whether they can compensate for the [Ca2+]i abnormality in ventricular myocytes is unknown. OBJECTIVE: We investigated whether enhanced Ca2+ uptake of mitochondria may compensate for an abnormal increase in the [Ca2+]i of ventricular myocytes in HF to effectively mitigate VA. METHODS: We used a HF mouse model, in which myocardial infarction was induced by permanent left anterior descending coronary artery ligation. The mitochondrial Ca2+ uniporter was stimulated by kaempferol. Ca2+ dynamics and membrane potential were measured using an epifluorescence microscope, a confocal microscope, and the perforated patch-clamp technique. VA was induced in the Langendorff-perfused hearts, and the hemodynamic parameters were measured using a microtip transducer catheter. RESULTS: Protein expression of the mitochondrial Ca2+ uniporter, as assessed by its subunit expression, did not change between HF and sham mice. Treatment of cardiomyocytes with kaempferol, isolated from HF mice at 28 days after coronary ligation, reduced the appearance of aberrant diastolic [Ca2+]i waves and sparks and spontaneous action potentials. Kaempferol effectively reduced the VA occurring in Langendorff-perfused hearts. Intravenous administration of kaempferol did not markedly affect the left ventricular hemodynamic parameters. CONCLUSION: The effects of kaempferol in HF of mice implied that mitochondria may have the potential to compensate for abnormal [Ca2+]i. Mechanisms involved in mitochondrial Ca2+ uptake may provide novel targets to treat HF-associated VA.
  • Suppression of Mitochondrial Oxidative Stress and Atrial Fibrillation Inducibility by SGLT2 Inhibitors in Diabetic Rats(和訳中)
    小泉 拓也; 渡邉 昌也; 横田 卓; 夏井 宏征; 門坂 崇秀; 甲谷 太郎; 中尾 元基; 萩原 光; 鎌田 塁; 天満 太郎; 安斉 俊久
    日本循環器学会学術集会抄録集, 86回, MPJ14, 4, (一社)日本循環器学会, 2022年03月
    英語
  • Pharmacological nNOS inhibition modified small conductance Ca2+-activated K+ channel without altering Ca2+ dynamics
    Taro Koya; Masaya Watanabe; Hiroyuki Natsui; Takahide Kadosaka; Takuya Koizumi; Motoki Nakao; Hikaru Hagiwara; Rui Kamada; Taro Temma; Toshihisa Anzai
    American journal of physiology. Heart and circulatory physiology, 323, 5, H869-H878, 2022年, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Atrial fibrillation (AF) is associated with electrical remodeling processes that promote a substrate for the maintenance of AF. Although the small-conductance Ca2+-activated K+ (SK) channel is a key factor in atrial electrical remodeling, the mechanism of its activation remains unclear. Regional nitric oxide (NO) production by neuronal nitric oxide synthase (nNOS) is involved in atrial electrical remodeling. In this study, atrial tachyarrhythmia (ATA) induction and optical mapping were performed on perfused rat hearts. nNOS is pharmacologically inhibited by S-methylthiocitrulline (SMTC). The influence of the SK channel was examined using a specific channel inhibitor, apamin (APA). Parameters such as action potential duration (APD), conduction velocity, and calcium transient (CaT) were evaluated using voltage and calcium optical mapping. The dominant frequency was examined in the analysis of AF dynamics. SMTC (100 nM) increased the inducibility of ATA and apamin (100 nM) mitigated nNOS inhibition-induced arrhythmogenicity. SMTC caused abbreviations and enhanced the spatial dispersion of APD, which was reversed by apamin. By contrast, conduction velocity and other parameters associated with CaT were not affected by SMTC or apamin administration. Apamin reduced the frequency of SMTC-induced ATA. In summary, nNOS inhibition abbreviates APD by modifying the SK channels. A specific SK channel blocker, apamin, mitigated APD abbreviation without alteration of CaT, implying an underlying mechanism of posttranslational modification of SK channels.NEW & NOTEWORTHY We demonstrated that pharmacological nNOS inhibition increased the atrial arrhythmia inducibility and a specific small-conductance Ca2+-activated K+ channel blocker, apamin, reversed the enhanced atrial arrhythmia inducibility. Apamin mitigated APD abbreviation without alteration of Ca2+ transient, implying an underlying mechanism of posttranslational modification of SK channels.
  • Hybrid epicardial ventricular tachycardia ablation with lateral thoracotomy in a patient with a history of left ventricular reconstruction surgery.
    Taro Koya; Masaya Watanabe; Rui Kamada; Hikaru Hagiwara; Motoki Nakao; Takahide Kadosaka; Takuya Koizumi; Toshihisa Anzai
    Journal of cardiology cases, 25, 1, 37, 41, Elsevier BV, 2022年01月, [査読有り], [筆頭著者], [国内誌]
    英語, 研究論文(学術雑誌), Although a hybrid procedure involving surgical access may be feasible for epicardial catheter ablation in individuals with prior cardiac surgery, surgical approaches in thoracotomy are important in patients with advanced adhesions. We performed an epicardial ventricular tachycardia (VT) ablation in a patient with dilated phase hypertrophic cardiomyopathy after left ventricular reconstruction. We gained surgical epicardial access via lateral thoracotomy based on the anticipated VT circuit in the apical anteroseptal area, which was estimated using prior endocardial mapping. The remaining epicardial myocardium around the surgical incision was involved in the central isthmus, and the VT was eliminated by radiofrequency catheter ablation. .
  • Epsilon wave disappearance by catheter ablation for ventricular arrhythmia from the left ventricular outflow tract.
    Hikaru Hagiwara; Masaya Watanabe; Rui Kamada; Taro Koya; Motoki Nakao; Toshihisa Anzai
    HeartRhythm case reports, 7, 5, 343, 346, 2021年05月, [国際誌]
    英語
  • Higher Pulmonary Arterial Pressure Was Related to Non-Pulmonary Vein Atrial Tachyarrhythmia.
    Wei-Chieh Lee; Masaya Watanabe; Hisashi Yokoshiki; Taro Temma; Rui Kamada; Hikaru Hagiwara; Yumi Takahashi; Taro Koya; Motoki Nakao; Toshihisa Anzai
    International heart journal, 61, 6, 1150, 1156, 2020年11月28日, [国内誌]
    英語, 研究論文(学術雑誌), Recurrence of atrial tachyarrhythmias (ATA) following catheter ablation for atrial fibrillation (AF) is often associated with the recovery of conduction into previously isolated pulmonary veins (PVs). Little evidence concerning repeat PV isolation (PVI) and non-PV ATA ablation has been reported. This study aimed to explore the clinical outcome of recurrent ATA ablation after PVI and the difference between patients with and without non-PV ATA.A total of 49 patients without structural heart diseases who received catheter ablation for recurrent AF between January 2014 and December 2018 were recruited (prior ablation with PVI only 71.4% and PVI with cavotricuspid isthmus line ablation 28.6%). Patients were divided into two groups according to the presence or absence of non-PV ATA.Most patients (53.1%) experienced very late recurrence with a median duration of 15 months. A total of 15 patients had non-PV ATA and received non-PV ATA ablation whereas 34 patients received only repeat PVI for reconnected PVs. A higher pulmonary arterial systolic pressure (PASP) was associated with non-PV ATA (odds ratio: 1.161; 95% confidence interval: 1.021-1.321; P = 0.023). During 4.7 ± 1 months, 4/15 (26.7%) and 1/34 (2.9%) patients with and without non-PV ATA, respectively, had ATA recurrence (P = 0.011). The cumulative incidence of ATA recurrence after repeat ablation was significantly lower in patients without non-PV ATA (P = 0.013).In our study, a high PASP was associated with non-PV ATA in patients with recurrent AF. Repeat PVI had a high rate of maintenance of sinus rhythm in patients without non-PV ATA.
  • 心臓サルコイドーシス患者でfragmented QRSは、心事故、慢性期致死性不整脈と関連する
    萩原 光; 渡邉 昌也; 中尾 元基; 甲谷 太郎; 小林 雄太; 加藤 喜哉; 小森山 弘和; 鎌田 塁; 永井 利幸; 安斉 俊久
    日本サルコイドーシス/肉芽腫性疾患学会雑誌, 40, サプリメント号, 56, 56, 日本サルコイドーシス, 2020年10月
    日本語
  • Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi.
    Shingo Tsujinaga; Hiroyuki Iwano; Tomohiro Oshino; Takahide Kadosaka; Yoshifumi Mizuguchi; Ko Motoi; Yasuyuki Chiba; Taro Koya; Taro Temma; Kiwamu Kamiya; Arata Fukushima; Takuya Koizumi; Tomoya Sato; Sakae Takenaka; Atsushi Tada; Suguru Ishizaka; Miwa Sarashina; Kazunori Omote; Rui Kamada; Takao Konishi; Takuma Sato; Toshiyuki Nagai; Hiroko Yamashita; Toshihisa Anzai
    Internal medicine (Tokyo, Japan), 59, 17, 2155, 2160, 2020年09月01日, [国内誌]
    英語, 研究論文(学術雑誌), Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart failure or arterial thromboembolism has been reported as a rare cardiovascular complication of bevacizumab. We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.
  • Successful epicardial ablation for ventricular tachycardia originating from the true apex of apical aneurysm associated with hypertrophic cardiomyopathy
    Motoki Nakao; Masaya Watanabe; Rui Kamada; Hikaru Hagiwara; Yumi Takahashi; Taro Koya; Takahide Kadosaka; Takuya Koizumi; Masanori Hirose; Toshihisa Anzai
    Journal of Electrocardiology, 61, 170, 174, 2020年07月
    英語, 研究論文(学術雑誌)
  • Radiofrequency catheter ablation of a sporadically occurring ventricular arrhythmia originating from the right ventricular outflow tract: A novel arrhythmia induction strategy involving atrial fibrillation provocation.
    Taro Koya; Taro Temma; Masaya Watanabe; Rui Kamada; Toshiyuki Nagai; Toshihisa Anzai
    HeartRhythm case reports, 6, 7, 411, 414, 2020年07月, [査読有り], [筆頭著者], [国際誌]
    英語
  • Differential Prognostic Impact of Atrial Fibrillation in Hospitalized Heart Failure Patients With Preserved Ejection Fraction According to Coronary Artery Disease Status - Report From the Japanese Nationwide Multicenter Registry.
    Taro Temma; Toshiyuki Nagai; Masaya Watanabe; Rui Kamada; Yumi Takahashi; Hikaru Hagiwara; Taro Koya; Motoki Nakao; Kazunori Omote; Kiwamu Kamiya; Hiroyuki Iwano; Kazuhiro Yamamoto; Tsutomu Yoshikawa; Yoshihiko Saito; Toshihisa Anzai
    Circulation journal : official journal of the Japanese Circulation Society, 84, 3, 397, 403, 2020年02月25日, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Atrial fibrillation (AF) is an important prognostic determinant in heart failure (HF) with preserved ejection fraction (HFpEF). However, it is unclear which HFpEF phenotypes are affected by AF in terms of long-term clinical outcomes because HFpEF is a heterogeneous syndrome with comorbidities such as coronary artery disease (CAD). In this study we determined the differential prognostic significance of AF in HFpEF patients according to CAD status.Methods and Results:Data for 408 hospitalized HFpEF patients enrolled in the Japanese Heart Failure Syndrome with Preserved Ejection Fraction Nationwide Multicenter Registry were analyzed. Patients were divided into 4 groups according to the presence of AF and CAD. The primary outcome was the composite of all-cause death and HF rehospitalization. The incidence of adverse events was higher in the AF-non-CAD than non-AF-non-CAD group (P=0.004). On multivariable Cox regression analysis with prespecified confounders, AF-non-CAD was significantly associated with an increased risk of adverse events than non-AF-non-CAD (adjusted HR, 1.91; 95% CI: 1.02-3.92) regardless of the type of AF. In contrast, risk was comparable between the AF-CAD and non-AF-CAD groups (adjusted HR, 1.24; 95% CI: 0.64-2.47). CONCLUSIONS: In HFpEF patients without CAD, AF was independently related to adverse events, indicating that intensive management of AF would have more beneficial effects particularly in HFpEF patients without CAD.
  • 心臓サルコイドーシス患者でfragmented QRSは,心事故,慢性期致死性不整脈と関連する
    萩原光; 渡邉昌也; 中尾元基; 甲谷太郎; 小林雄太; 加藤喜哉; 小森山弘和; 鎌田塁; 永井利幸; 安斉俊久
    日本サルコイドーシス/肉芽腫性疾患学会雑誌, 40, サプリメント号, 56, 56, 日本サルコイドーシス, 2020年10月
    日本語
  • 心筋梗塞後偽性仮性左室瘤に収縮性心膜炎の合併が考えられた1例
    甲谷太郎; 神谷究; 千葉泰之; 岩野弘幸; 納谷昌直; 永井利幸; 松居喜郎; 安斉俊久
    日本心臓病学会学術集会(Web), 67th, P, 180, (一社)日本心臓病学会, 2019年09月
    日本語
■ その他活動・業績
■ 書籍等出版物
  • ホスピタリスト
    甲谷太郎; 永井利幸, 心房細動合併の慢性心不全患者は全例アブレーションをすべきか?
    メディカル・サイエンス・インターナショナル, 2021年09月, 9784815720032, [査読有り], [共著]
  • 循環器専門医
    甲谷 太郎; 安斉 俊久, 症例報告 心筋梗塞後偽性仮性左室瘤に収縮性心膜炎の合併が考えられた1例
    一般社団法人 日本循環器学会, 2021年08月, 169, 118-123, [共著]
  • 重症心不全治療プラクティス
    安斉 俊久, Case Study⑧:補助人工心臓手術後に弁膜症が進行したケース
    南江堂, 2020年03月, 192, 149-152, 教科書・概説・概論, [分担執筆]
  • ホスピタリスト
    甲谷太郎; 永井利幸, 急性心不全で退院までにすべきこと
    メディカル・サイエンス・インターナショナル, 2018年, 1071, 964-974, 日本語, 教科書・概説・概論, [査読有り], [共著]
■ 所属学協会
  • 2022年02月 - 現在
    米国不整脈学会
  • 2022年 - 現在
    日本人工臓器学会
  • 2022年 - 現在
    日本心不全学会
  • 2019年 - 現在
    日本不整脈心電学会
  • 2019年 - 現在
    日本心臓病学会
  • 2015年 - 現在
    日本循環器学会
  • 2014年 - 現在
    日本内科学会
■ 共同研究・競争的資金等の研究課題